An approved LGSOC drug funds the runway while a KRAS G12D inhibitor races three simultaneous registration trials — proof of efficacy in Phase 2 is the make-or-break condition

Bull

A positive outcome would be objective response rates and tumor shrinkage data across PDAC, NSCLC, and CRC cohorts that confirm and extend the Phase 1 signal — specifically, ORRs materially above historical chemotherapy benchmarks in each indication, durable responses, and continued absence of on-target panRAS toxicities. Such data would de-risk the accelerated approval pathway, support the FDA Phase 3 design meeting, and establish VS-7375 as a credible KRAS G12D franchise across multiple high-prevalence tumor types, potentially rerating the stock on pipeline optionality alone.

Bear

The most likely failure modes are response rates that are numerically encouraging in Phase 1 but fail to hold up at registrational doses in larger, less selected Phase 2 cohorts, or that fall short of the bar needed to differentiate from standard-of-care chemotherapy regimens in first-line mPDAC and mCRC. A second risk is emerging toxicity signals at the 900 mg dose or in combinations that force dose reductions, narrowing the therapeutic window and complicating pivotal trial design; either outcome would call into question the viability of three simultaneous Phase 3 programs and the company's ability to sustain the runway provided by AVMAPKI FAKZYNJA revenue.